Rachael Tromley
Family · Oklahoma City, OKNPI 1790765733
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,883 and has fallen 55.1% since, to $845 in 2025. Among family clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$655
- Otsuka America Pharmaceutical, Inc.$605
- Johnson & Johnson$474
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$344
- Noven Therapeutics, LLC$314
- Axsome Therapeutics, Inc.$297
- plus $1K from 12 others
What the payments were for
- Food & beverage$4,063100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $655 |
| Otsuka America Pharmaceutical, Inc. | 32 | $605 |
| Johnson & Johnson | 10 | $474 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $344 |
| Noven Therapeutics, LLC | 16 | $314 |
| Axsome Therapeutics, Inc. | 6 | $297 |
| Supernus Pharmaceuticals, Inc. | 5 | $209 |
| Corium, LLC | 4 | $200 |
| Teva Pharmaceuticals USA, Inc. | 6 | $192 |
| Alkermes, Inc. | 3 | $166 |
| Neurocrine Biosciences, Inc. | 8 | $140 |
| Bausch Health US, LLC | 7 | $137 |
| Noven Pharmaceuticals, Inc. | 1 | $121 |
| Ironshore Pharmaceuticals Inc. | 4 | $75 |
| Lundbeck LLC | 2 | $55 |
| Vanda Pharmaceuticals Inc. | 1 | $32 |
| Sage Therapeutics, LLC | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,063 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 15 | $134 |
| Escitalopram Oxalate | 14 | $30 |
Paid to pharmacies, not to this prescriber.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.